Spyre Therapeutics Inc (NASDAQ:SYRE)
| 19.44 Delayed Data As of Dec 01 |  +0.78 / +4.18%Today’s Change | 2.66 Today|||52-Week Range 24.00 | +72.84% Year-to-Date |
Latest SYRE News | Press Releases
No recent news for Spyre Therapeutics Inc.
Today’s Trading
| Previous close | 18.66 |
| Today’s open | 18.67 |
| Day’s range | 16.72 - 21.72 |
| Volume | 1,962 |
| Average volume (3 months) | 41,412 |
| Market cap | $792.8M |
Data as of 3:56pm ET, 12/01/2023
Growth & Valuation
| Earnings growth (last year) | +0.64% |
| Earnings growth (this year) | +98.32% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -87.57% |
| P/E ratio | NM |
| Price/Sales | 16.28 |
| Price/Book | 0.86 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| AGENAgenus Inc | +0.01 | +1.13% |
| PGENPrecigen Inc | +0.06 | +5.36% |
| FATEFate Therapeutics In... | +0.16 | +6.43% |
| ALPNAlpine Immune Scienc... | +0.10 | +0.65% |
Data as of 4:00pm ET, 12/01/2023
Financials
| Next reporting date | March 13, 2024 |
| EPS forecast (this quarter) | -$0.04 |
| Annual revenue (last year) | $2.3M |
| Annual profit (last year) | -$83.8M |
| Net profit margin | -3,598.75% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Waltham, Massachusetts |
Forecasts
